Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.

Lodise, Thomas P; Redell, Mark; Armstrong, Shannon O; Sulham, Katherine A; Corey, G Ralph

Lodise, Thomas P; Redell, Mark; Armstrong, Shannon O; Sulham, Katherine A; Corey, G Ralph.

Afiliação

Lodise TP; Albany College of Pharmacy and Health Sciences, New York.
Redell M; The Medicines Company, Parsippany, New Jersey.
Armstrong SO; The Medicines Company, Parsippany, New Jersey.
Sulham KA; The Medicines Company, Parsippany, New Jersey.
Corey GR; Duke University Medical Center, Durham, North Carolina.

Open Forum Infect Dis ; 4(1): ofw274, 2017.

Article em En | MEDLINE | ID: mdl-28480266

Palavras-chave

ABSSSI; long-acting lipoglycopeptides; oritavancin; skin infections; vancomycin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google